121 Peptide CRO and CDMO vendors

What does it take to develop and manufacture a peptide drug?

Peptides sit in an awkward middle ground between small molecules and biologics, and that is exactly why vendor fit matters so much. A peptide is built one amino acid at a time, usually by solid-phase peptide synthesis (SPPS), and every coupling step is a chance to introduce a deletion sequence, a racemized residue, or an aggregation problem you will spend weeks chasing later. The chemistry that makes a clean 12-mer is not the chemistry that makes a 40-residue therapeutic with three disulfide bridges, a lipid conjugate, or a head-to-tail cyclization. So the first thing to settle with any provider is whether they have actually made molecules like yours, at the length and complexity you need, not whether they run a peptide synthesizer.

Early on, the work is discovery and optimization: sequence design, analog synthesis, stability and protease-resistance screening, and the modifications that turn a fragile native peptide into a drug (N-methylation, unnatural amino acids, PEGylation or lipidation for half-life, cyclization for rigidity and target selectivity). This is largely non-GLP, decision-grade chemistry, and a discovery-focused peptide CRO lives here. As you move toward the clinic, the center of gravity shifts to CMC and manufacturing: a defined synthesis route, validated purification (almost always preparative reverse-phase HPLC), and an analytical package that nails down identity, purity, counterion and water content, and the impurity profile. Mass spec, analytical HPLC, amino acid analysis, and chiral or peptide-mapping methods all earn their place here.

This is where specialist peptide CDMOs pull away from generalist chemical manufacturers. A shop that is excellent at small-molecule API may underestimate how much a peptide program lives or dies on purification capacity and on controlling closely related impurities (single-residue deletions, oxidation, diastereomers) that a routine HPLC method will not even separate. Specialists bring large-scale SPPS or hybrid solution-phase routes, the prep-HPLC and lyophilization throughput to actually make kilograms, and analysts who have characterized these impurity classes before. Longer or more modified peptides push you firmly toward a specialist; a short, simple linear peptide gives you more room to use a capable generalist.

How do you choose a CRO or CDMO for peptide work?

Start with fit to your specific molecule, not the size of the logo or the headline price. Score two or three vendors against the same written scope (the sequence, the length, the modifications, the scale, and the purity spec you need) so the quotes measure the same work rather than three differently shaped guesses. The cheapest quote on a complex peptide is rarely the cheapest outcome, because a failed batch or an impurity you cannot clear forces a repeat that costs you months. Work the checklist below.

• Relevant platform and track record: confirm they routinely make peptides of your length and type (linear, cyclic, stapled, disulfide-rich, conjugated or lipidated) and ask to see comparable structures they have produced, not a generic capabilities slide. SPPS depth, plus solution-phase or hybrid routes for longer sequences and larger scale, is the real differentiator.
• GxP status and analytical capability for this modality: match the quality system to your stage. Research analogs run non-GLP; IND-enabling and clinical material need GMP drug substance with full release testing. Confirm the analytical toolkit handles peptides specifically: prep and analytical RP-HPLC, LC-MS and high-res mass spec, amino acid analysis, peptide mapping, counterion and water (Karl Fischer) content, and methods that resolve deletion sequences and diastereomers, not just a single purity number.
• Capacity and scale: ask how much they can actually make at your stage and whether they can carry you from grams to kilograms without a technology transfer to a different site. Purification throughput (prep-HPLC columns and loading) and lyophilization capacity are the usual bottlenecks, so probe those, not just synthesizer count. Check current queue and realistic lead time, since a strong lab booked solid can be slower than a good lab with an open slot.
• Regulatory experience: for clinical material, confirm they have supported INDs or equivalent filings with peptide drug substance, can supply the CMC sections and method validation a regulator will scrutinize, and understand the impurity qualification and specification-setting that peptides demand. Stability program design and ICH-aligned storage data matter once you are in the clinic.
• IP and confidentiality: get a CDA in place before you disclose your sequence, since the sequence itself is the asset. Settle ownership of process know-how, any vendor-developed synthesis or purification improvements, and the analytical methods, in writing before work starts.